Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
12/19/16

Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva

12/06/16

Results from Ongoing Phase 2b Study in Gastroparesis Expected in Mid-2017

12/05/16

Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva

11/22/16
DUBLIN , Nov. 22, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) announced today that members of management will participate in a fireside chat at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 10:00 a.m.
11/21/16

Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva<br>GSK on Track for European Regulatory Submission for Closed Triple in COPD by end of 2016

11/08/16
DUBLIN , Nov. 8, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today reported financial results for the third quarter ended September 30, 2016 . Revenue for the third quarter 2016 was $19.1 million .
11/01/16
DUBLIN , Nov. 1, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended September 30, 2016 after market close on Tuesday, November 8, 2016 .
11/01/16

Retrospective Analyses of VIBATIV (telavancin) in Osteomyelitis Patients and in vitro Potency in Challenging Pathogens

10/31/16

TOUR Results Highlight Clinical Response Rates for VIBATIV&#174; (telavancin) in a Range of Difficult-to-Treat Infections; Real-World Use of Antibiotic Observed in Approved Indications, as well as Bone and Joint Infections and Bacteremia

10/28/16
DUBLIN , Oct. 27, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced the pricing of concurrent underwritten public offerings of 3,850,000 ordinary shares (the "Shares") at a price to the public of $26.00 per share and $200